GLP-1/GIP receptor agonist
Novo Nordisk and Vivtex partner in deal worth up to $2.1bn
The companies aim to develop next-generation oral medicines for obesity and diabetes
Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research
The companies are working together on cellular medicines to boost, replace or repair biological functions
Regeneron’s Lynozyfic granted FDA accelerated approval to treat multiple myeloma
More than 36,000 new cases of the blood cancer are expected to be diagnosed in the US this year
Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa
The company is planning to submit regulatory applications for the candidate by the end of the year
Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn
The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study
Regeneron to acquire human genetics company 23andMe for $256m
The agreement comes two months after 23andMe filed for bankruptcy protection
Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma
More than 35,000 new cases of the blood cancer are diagnosed every year in Europe
Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer
Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year
Eli Lilly announces $3bn expansion to US injectables manufacturing facility
The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines
Sanofi unveils plans to build €1bn insulin production base in China
The site will focus on serving the insulin medication needs of local diabetic patients
Common antidiabetic drug metformin found to slow growth of precancerous cells
The findings suggest that the drug could be used to manage squamous oesophageal cancer risk
Eli Lilly’s once-weekly insulin candidate shows promise in late-stage diabetes trials
It is hoped that a once-weekly treatment option could improve adherence rates